Thus, the approval of the first glucagon-like peptide-1 (GLP-1) receptors agonist (GLP-1 RAs) in the treatment of T2DM, with structures similar to endogenous hormones, opened a new era in promoting weight loss and improving health outcomes in obese people, including those with comorbidities [14]. Here, GLP1R is linked to type 2 diabetes mellitus.